CORCEPT THERAPEUTICS INC Increase Decrease In Operating Lease Liability
CORCEPT THERAPEUTICS INC (CORT) reported Increase Decrease In Operating Lease Liability of -$829.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-02-24
- CORCEPT THERAPEUTICS INC increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$251.00K, a 273.10% decline year-over-year.
- CORCEPT THERAPEUTICS INC increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$247.00K, a 273.94% decline year-over-year.
- CORCEPT THERAPEUTICS INC increase decrease in operating lease liability for the quarter ending 2025-06-30 was -$230.00K.
- CORCEPT THERAPEUTICS INC increase decrease in operating lease liability for the quarter ending 2025-03-31 was -$101.00K.
- CORCEPT THERAPEUTICS INC increase decrease in operating lease liability for fiscal 2025 was -$829.00K, a 553.01% decline from fiscal 2024.
- CORCEPT THERAPEUTICS INC increase decrease in operating lease liability for fiscal 2024 was $183.00K.
- CORCEPT THERAPEUTICS INC increase decrease in operating lease liability for fiscal 2023 was -$1.29M.
- CORCEPT THERAPEUTICS INC increase decrease in operating lease liability for fiscal 2022 was -$2.20M.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$251.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$498.00K derived: sum of 2 quarters · filed 2026-02-24 | -$728.00K derived: sum of 3 quarters · filed 2026-02-24 | -$829.00K 10-K · filed 2026-02-24 |
| 2025-09-30 | -$247.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$477.00K derived: sum of 2 quarters · filed 2025-11-04 | -$578.00K 10-Q · filed 2025-11-04 | -$433.00K derived: sum of 4 quarters · filed 2026-02-24 |
| 2025-06-30 | -$230.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | -$331.00K 10-Q · filed 2025-07-31 | -$186.00K derived: sum of 3 quarters · filed 2026-02-24 | -$44.00K derived: sum of 4 quarters · filed 2026-02-24 |
| 2025-03-31 | -$101.00K 10-Q · filed 2025-05-05 | $44.00K derived: sum of 2 quarters · filed 2026-02-24 | $186.00K derived: sum of 3 quarters · filed 2026-02-24 | $157.00K derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-12-31 | $145.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $287.00K derived: sum of 2 quarters · filed 2026-02-24 | $258.00K derived: sum of 3 quarters · filed 2026-02-24 | $183.00K 10-K · filed 2026-02-24 |
| 2024-09-30 | $142.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $113.00K derived: sum of 2 quarters · filed 2025-11-04 | $38.00K 10-Q · filed 2025-11-04 | -$36.00K derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | -$29.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | -$104.00K 10-Q · filed 2025-07-31 | -$178.00K derived: sum of 3 quarters · filed 2026-02-24 | -$250.00K derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | -$75.00K 10-Q · filed 2025-05-05 | -$149.00K derived: sum of 2 quarters · filed 2026-02-24 | -$221.00K derived: sum of 3 quarters · filed 2026-02-24 | -$796.00K derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | -$74.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$146.00K derived: sum of 2 quarters · filed 2026-02-24 | -$721.00K derived: sum of 3 quarters · filed 2026-02-24 | -$1.29M 10-K · filed 2026-02-24 |
| 2023-09-30 | -$72.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | -$647.00K derived: sum of 2 quarters · filed 2024-10-30 | -$1.22M 10-Q · filed 2024-10-30 | -$1.78M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | -$575.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-29 | -$1.14M 10-Q · filed 2024-07-29 | -$1.71M derived: sum of 3 quarters · filed 2025-02-26 | -$2.26M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | -$568.00K 10-Q · filed 2024-05-01 | -$1.13M derived: sum of 2 quarters · filed 2025-02-26 | -$1.69M derived: sum of 3 quarters · filed 2025-02-26 | -$2.24M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | -$564.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | -$1.12M derived: sum of 2 quarters · filed 2025-02-26 | -$1.67M derived: sum of 3 quarters · filed 2025-02-26 | -$2.20M 10-K · filed 2025-02-26 |
| 2022-09-30 | -$557.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | -$1.11M derived: sum of 2 quarters · filed 2023-11-01 | -$1.64M 10-Q · filed 2023-11-01 | -$2.15M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | -$552.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | -$1.08M 10-Q · filed 2023-08-02 | -$1.60M derived: sum of 3 quarters · filed 2024-02-15 | -$2.11M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | -$526.00K 10-Q · filed 2023-05-03 | -$1.05M derived: sum of 2 quarters · filed 2024-02-15 | -$1.56M derived: sum of 3 quarters · filed 2024-02-15 | -$2.07M derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | -$520.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | -$1.03M derived: sum of 2 quarters · filed 2024-02-15 | -$1.54M derived: sum of 3 quarters · filed 2024-02-15 | -$2.02M 10-K · filed 2024-02-15 |
| 2021-09-30 | -$513.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$1.02M derived: sum of 2 quarters · filed 2022-11-03 | -$1.50M 10-Q · filed 2022-11-03 | -$1.99M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | -$508.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$992.00K 10-Q · filed 2022-08-04 | -$1.47M derived: sum of 3 quarters · filed 2023-02-28 | -$1.95M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | -$484.00K 10-Q · filed 2022-05-05 | -$964.00K derived: sum of 2 quarters · filed 2023-02-28 | -$1.44M derived: sum of 3 quarters · filed 2023-02-28 | |
| 2020-12-31 | -$480.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$954.00K derived: sum of 2 quarters · filed 2023-02-28 | -$1.69M 10-K · filed 2023-02-28 | |
| 2020-09-30 | -$474.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | -$1.21M 10-Q · filed 2021-11-03 | ||
| 2020-06-30 | -$731.00K 10-Q · filed 2021-07-29 | |||
| 2019-12-31 | -$1.45M 10-K · filed 2022-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |